Thrombocytopenia - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 163
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T11102ED37BEN
Leaflet:

Download PDF Leaflet

Thrombocytopenia - Pipeline Review, H2 2016
Thrombocytopenia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombocytopenia – Pipeline Review, H2 2016, provides an overview of the Thrombocytopenia (Hematological Disorders) pipeline landscape.

Thrombocytopenia is characterized by an abnormally low amount of platelets Low platelet levels occur due to less production of platelets in the bone marrow, increased breakdown of platelets in the bloodstream or in the spleen or liver. Symptoms include bleeding in the mouth and gums, bruising, nosebleeds and rashes. Treatment includes transfusion of platelets to stop or prevent bleeding.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thrombocytopenia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Thrombocytopenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thrombocytopenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombocytopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 10, 6, 1, 13 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.Thrombocytopenia.

Thrombocytopenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombocytopenia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Thrombocytopenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thrombocytopenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thrombocytopenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thrombocytopenia (Hematological Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thrombocytopenia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thrombocytopenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Thrombocytopenia Overview
Therapeutics Development
Pipeline Products for Thrombocytopenia - Overview
Pipeline Products for Thrombocytopenia - Comparative Analysis
Thrombocytopenia - Therapeutics under Development by Companies
Thrombocytopenia - Therapeutics under Investigation by Universities/Institutes
Thrombocytopenia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Thrombocytopenia - Products under Development by Companies
Thrombocytopenia - Products under Investigation by Universities/Institutes
Thrombocytopenia - Companies Involved in Therapeutics Development

3SBIO INC.

AkaRx Inc
Amarillo Biosciences, Inc.
Amgen Inc.
arGEN-X BV
BioLineRx, Ltd.
Biotest AG
Boehringer Ingelheim GmbH
Bolder Biotechnology, Inc.
Bristol-Myers Squibb Company
Cellerant Therapeutics, Inc.
Genosco
Hansa Medical AB
Immunomedics, Inc.
Intas Pharmaceuticals Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Merck & Co., Inc.
Momenta Pharmaceuticals, Inc.
Myelo Therapeutics GmbH
Neumedicines Inc.
Novartis AG
Pfizer Inc.
PhytoHealth Corporation
Prophylix Pharma AS
Protalex, Inc.
Rigel Pharmaceuticals, Inc.
Shionogi & Co., Ltd.
Shire Plc
STATegics, Inc.

UCB SA

ViroMed Co Ltd
Thrombocytopenia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Antibody for Autoimmune Disorders and Inflammation - Drug Profile
ARGX-113 - Drug Profile
avatrombopag - Drug Profile
BBT-059 - Drug Profile
BI-655064 - Drug Profile
BL-8040 - Drug Profile
BMS-986004 - Drug Profile
BT-595 - Drug Profile
CLT-009 - Drug Profile
eltrombopag olamine - Drug Profile
eltrombopag olamine - Drug Profile
fostamatinib disodium - Drug Profile
GL-2045 - Drug Profile
GSK-2285921 - Drug Profile
Hetrombopag Olamine - Drug Profile
interferon alfa - Drug Profile
lusutrombopag - Drug Profile
M-281 - Drug Profile
MK-8723 - Drug Profile
Monoclonal Antibody to Agonize Thrombopoietin Receptor for Thrombocytopenia - Drug Profile
Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile
Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile
Myelo-001 - Drug Profile
NMIL-121 - Drug Profile
Oligonucleotides to Activate miRNA-150 for Thrombocytopenia and Anemia - Drug Profile
PEG-VM501 - Drug Profile
PHN-013 - Drug Profile
PRTX-100 - Drug Profile
Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile
romiplostim - Drug Profile
romiplostim biosimilar - Drug Profile
SHP-652 - Drug Profile
SKIO-703 - Drug Profile
Small Molecules to Inhibit BLVRB for Thrombocytopenia - Drug Profile
Small Molecules to Inhibit PF4 for Heparin Induced Thrombocytopenia - Drug Profile
STST-4 - Drug Profile
thrombopoietin - Drug Profile
Tromplate - Drug Profile
TXA-302 - Drug Profile
UCB-7665 - Drug Profile
veltuzumab - Drug Profile
Thrombocytopenia - Dormant Projects
Thrombocytopenia - Discontinued Products
Thrombocytopenia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 160

LIST OF TABLES

Number of Products under Development for Thrombocytopenia, H2 2016
Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Thrombocytopenia - Pipeline by 3SBio Inc., H2 2016
Thrombocytopenia - Pipeline by AkaRx Inc, H2 2016
Thrombocytopenia - Pipeline by Amarillo Biosciences, Inc., H2 2016
Thrombocytopenia - Pipeline by Amgen Inc., H2 2016
Thrombocytopenia - Pipeline by arGEN-X BV, H2 2016
Thrombocytopenia - Pipeline by BioLineRx, Ltd., H2 2016
Thrombocytopenia - Pipeline by Biotest AG, H2 2016
Thrombocytopenia - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Thrombocytopenia - Pipeline by Bolder Biotechnology, Inc., H2 2016
Thrombocytopenia - Pipeline by Bristol-Myers Squibb Company, H2 2016
Thrombocytopenia - Pipeline by Cellerant Therapeutics, Inc., H2 2016
Thrombocytopenia - Pipeline by Genosco, H2 2016
Thrombocytopenia - Pipeline by Hansa Medical AB, H2 2016
Thrombocytopenia - Pipeline by Immunomedics, Inc., H2 2016
Thrombocytopenia - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
Thrombocytopenia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
Thrombocytopenia - Pipeline by Merck & Co., Inc., H2 2016
Thrombocytopenia - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
Thrombocytopenia - Pipeline by Myelo Therapeutics GmbH, H2 2016
Thrombocytopenia - Pipeline by Neumedicines Inc., H2 2016
Thrombocytopenia - Pipeline by Novartis AG, H2 2016
Thrombocytopenia - Pipeline by Pfizer Inc., H2 2016
Thrombocytopenia - Pipeline by PhytoHealth Corporation, H2 2016
Thrombocytopenia - Pipeline by Prophylix Pharma AS, H2 2016
Thrombocytopenia - Pipeline by Protalex, Inc., H2 2016
Thrombocytopenia - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016
Thrombocytopenia - Pipeline by Shionogi & Co., Ltd., H2 2016
Thrombocytopenia - Pipeline by Shire Plc, H2 2016
Thrombocytopenia - Pipeline by STATegics, Inc., H2 2016
Thrombocytopenia - Pipeline by UCB SA, H2 2016
Thrombocytopenia - Pipeline by ViroMed Co Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Thrombocytopenia - Dormant Projects, H2 2016
Thrombocytopenia - Dormant Projects (Contd..1), H2 2016
Thrombocytopenia - Dormant Projects (Contd..2), H2 2016
Thrombocytopenia - Discontinued Products, H2 2016 148

LIST OF FIGURES

Number of Products under Development for Thrombocytopenia, H2 2016
Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Symphogen A/S - Product Pipeline Review - 2015 US$ 1,200.00 Jul, 2015 · 42 pages

Ask Your Question

Thrombocytopenia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: